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cense. httpAbstract Background: Breast cancer in Egypt is the most common cancer among women and is
the leading cause of cancer mortality. Traditionally, axillary lymph node involvement is considered
among the most important prognostic factors in breast cancer. Nonetheless, accumulating evidence
suggests that axillary lymph node ratio should be considered as an alternative to classical pN clas-
siﬁcation.
Materials and methods: We performed a retrospective analysis of patients with operable node-
positive breast cancer, to investigate the prognostic signiﬁcance of axillary lymph node ratio.
Results: Five-hundred patients were considered eligible for the analysis. Median follow-up was
35 months (95% CI 32–37 months), the median disease-free survival (DFS) was 49 months (95%
CI, 46.4–52.2 months). The classiﬁcation of patients based on pN staging system failed to prognos-
ticate DFS in the multivariate analysis. Conversely, grade 3 tumors, and the intermediate (>0.20 to
60.65) and high (>0.65) LNR were the only variables that were independently associated with
adverse DFS. The overall survival (OS) in this series was 69 months (95% CI 60–77).
Conclusion: The analysis of outcome of patients with early breast cancer in Egypt identiﬁed the
adverse prognostic effects of high tumor grade, ER negativity and intermediate and high LNR
on DFS. If the utility of the LNR is validated in other studies, it may replace the use of absolute
number of axillary lymph nodes.
ª 2013 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.ulty of Medicine, Mansoura
gypt. Tel.: +20 1007291213.
om (T.R. Elkhodary).
e National Cancer Institute,
g by Elsevier
Open access under CC BY-NC-ND license.
ng by Elsevier B.V. on behalf of N
://dx.doi.org/10.1016/j.jnci.2013.10Background
In Egypt, breast cancer is estimated to be the most common
cancer among females accounting for 37.7% of their total with
12,621 new cases in 2008. It is also the leading cause of cancer
related mortality accounting for 29.1% of their total with 6546ational Cancer Institute, Cairo University.
.001
32 T.R. Elkhodary et al.deaths [1]. These estimates are conﬁrmed in many regional
Egyptian cancer registries [2,3].
There are variations in breast cancer patterns between
developed and developing countries. Higher tumor stage at
diagnosis due to the lack of widely implemented national
screening programs in Egypt just started few years ago [4]. Also
younger age is perhaps more seen in developing nations too and
this could be well explained by the different population
pyramids being predominantly young in the developing coun-
tries [5].
Traditionally, axillary lymph node involvement and the
increasing absolute number of positive lymph nodes (pN) are
considered among the most important prognostic factors in
breast cancer [6–8]. Nonetheless, in a recent report using the
Geneva Cancer Registry data, the authors established that cer-
tain identiﬁed cutoff points for axillary lymph node ratio
(LNR; ratio of positive over excised lymph nodes) predicted
breast cancer survival more accurately than the classical pN
classiﬁcation [9]. The report recommended that LNR should
be considered as an alternative to the pN staging. Similarly,
a systematic review of 24 articles including 32,299 patients,
also concluded that the LNR was superior to the number of
involved nodes as a prognostic indicator [10]. New evidence
has continued to accrue conﬁrming the prognostic signiﬁcance
of nodal ratios in various worldwide population settings [11].
The analysis of the survival outcome of mostly young patients
with early breast cancer in Saudi Arabia identiﬁed the adverse
prognostic effects of young age, high grade of tumor and
intermediate and high LNR on DFS [12]. Prompted by these
reports and inﬂuenced by the above allotted differences in
breast cancer patterns in Egypt compared with that in Western
countries, we planned this analysis to examine the prognostic
role of LNR on disease free survival (primary objective) and
overall survival (secondary objective) of patients with breast
cancer. We also intended to highlight the clinicopathologic fea-
tures of breast cancer in our locality.Materials and methods
We conducted a retrospective review of 1290 breast cancer
patients treated at the Oncology center, Mansoura University
between April 2006 and May 2012. Data were retrieved from
the electronic hospital-based cancer registry database of the
Department of Oncology at Mansoura University Oncology
Center, Mansoura, Egypt, until May 2013. Only patients
with invasive non-metastatic breast cancer, who underwent
axillary lymph node dissection and had one or more positive
axillary lymph nodes, were considered eligible. Patients must
not have received neoadjuvant chemotherapy. The ﬁnal
number available was 500 patients, representing the study
population.
A database was constructed to record the following infor-
mation for each patient: patient characteristics, diagnostic
methods, histological features of the tumor including immuno-
histochemistry, number of dissected and positive lymph nodes,
LNR, treatment details, recurrence data, survival, and cause of
death. For the survival analysis, we used the LNR cutoff val-
ues as identiﬁed by Vinh-Hung et al. [9]. The endpoints for the
survival analyses were disease-free (DFS) and overall survival
(OS). For patients who were lost to follow-up, their survival
status at last contact was used.Deﬁnitions
Disease stage was deﬁned according to the criteria laid down
by the International Union Against Cancer, with group clinical
and pathological staging according to the American Joint
Committee on Cancer. OS was estimated from date of diagno-
sis to date of last follow-up or death from breast cancer. DFS
was deﬁned as the time between date of surgery and date of
last follow-up or date of best available evidence of the ﬁrst
unfavorable event: local recurrence, locoregional recurrence,
distant metastases, or death. Loco-regional recurrence was
deﬁned as any recurrence in the ipsilateral, chest wall, or
lymph node. Contralateral breast recurrence was considered
as distant metastases.
Statistical methods
Survival functions were estimated applying the method of
Kaplan and Meier [13], while the statistical procedure of
Brookmeyer–Crowley was used to estimate the 95% conﬁdence
interval (CI) of median survival [14]. The log-rank test was used
to assess the signiﬁcance of unadjusted differences in survival
[15]. Exploring variables for their independent prognostic effect
on survival was carried out using the multivariate stepwise
Cox’s proportional regression hazard model [16,17], and the
goodness of ﬁt was judged by plotting the cumulative
baseline hazard function for residuals [18]. We also compared
the survival functions for variables after stratifying for
baseline differences in additional variables [19]. A two-tailed
p value of <0.05 was considered statistically signiﬁcant. The
software IBM-SPSS version 20 was used for all statistical
evaluations. The study was approved by the Institutional
Review Board.Results
Five-hundred patients were considered eligible for the analysis.
None of the patients had sentinel node procedure.
Table 1 depicts patient and disease characteristics. The
mean age was 50 years, with 12% (60 patients) and 88%
(440 patients) below and above 35 years, respectively. Patients
in this series showed a relatively high prevalence of poor prog-
nostic features: 90.6% had more than T1 tumor, 92.8% pre-
sented with grade 2 or 3 tumors, 63% and 30.4% had 4 or
more and 10 or more positive lymph nodes respectively,
around 34.3% had negative ER, and 70% had intermediate
or high LNR. Moreover, the median tumor size was 3.7 cm,
with 24% and 8% of patients having tumor P5 and
P10 cm, respectively.
The median follow-up was 35 months (95% CI
32–37 months), the minimum follow up was 12 months while
the maximum follow up was 82 months.Disease-free survival
The median DFS was 49 months (95% CI 46.4–52.2 months).
Table 2 shows the univariate analysis of the inﬂuence of
various factors on DFS. Patient age 635 years, T2, T3 or T4
tumor, tumor that was grade 2 or 3, tumor that was N2 or
N3, tumor with intermediate or high LNR, and ER or PR
Table 1 Patients and disease characteristics.
Parameter No. %
Age (years) Mean (SD) 50 (11)
635 60 12.0
>35 440 88.0
T stage T1 47 9.4
T2 276 55.2
T3 156 31.2
T4 21 4.2
Tumor grade GI 36 7.2
GII 369 73.8
GIII 95 19.0
LN stage pN1 185 37.0
pN2 163 32.6
pN3 152 30.4
LN ratio Median (range) 0.4 (0.04–1.0)
60.2 150 30.0
0.2 & 60.65 190 38.0
>0.65 160 32.0
ER (496 cases) ER-ve 170 34.3
ER+ ve 326 65.7
PR (496 cases) PR-ve 163 32.9
PR+ ve 333 67.1
Her-2 status (277 cases) Her-2- 215 77.6
Her-2+ 62 22.4
Surgery MRM 467 93.4
BCS 33 6.6
Adjuvant chemotherapy No chemotherapy 14 2.8
Anthracycline-based 263 52.6
Anthracycline & taxane 211 42.2
Others 12 2.4
Adjuvant endocrine therapy No endocrine therapy 185 37.0
Tamoxifen 257 51.4
Aromatase inhibitor 19 3.8
Tamoxifen and aromatase inhibitor 39 7.8
Adjuvant radiotherapy No radiotherapy 126 25.2
Adjuvant radiotherapy 374 74.8
Relapse site (205 cases) Skin & LNs 43
Bone 39
Lung 28
Liver 32
Multiple 64
Brain 7
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The LNR delineates DFS differences between the three risk
categories (Fig. 1). Variables found signiﬁcant in the univariate
analysis were tested in the multivariate Cox regression analy-
sis. Table 3 shows that grade 3 tumors, ER negativity, and
the intermediate and high LNR categories were the only vari-
ables that were independently associated with adverse DFS. In
that multivariate analysis, compared with patients within the
low LNR risk group, the hazard ratio of breast cancer recur-
rence risk was 2.2 (95% CI 1.5–4.9) for patients in the interme-
diate LNR risk group and 3.2 (95% CI 1.9–5.5) for patients
within the high LNR risk group. Classifying patients according
to pN1, pN2, or pN3 status was not predictive for DFS.Overall survival
The OS of the 500 patients in this series was 69 months (95%
CI 60–77). Only ER ve tumor was shown to adversely inﬂu-
ence OS with 2-fold (95% CI 1.4–2.9), an increase in the risk of
dying of breast cancer.
Discussion
Recognizing that axillary lymph node status is the most pow-
erful predictor of outcome for women with breast cancer [6,7],
the new American Joint Committee on Breast Cancer staging
Table 2 Univariate analysis of the effects of prognostic variables on DFS.
Variable No. Median DSF (months) 3 Year DFS (%) p Hazard ratio 95.0% CI
Age 0.03
635 60 34 61 1.55 1.09–2.29
>35 440 51 79 1
T stage <0.001
T1 47 58 81 1
T2 276 51 77 0.11 1.55 0.93–2.79
T3 156 42 50 0.001 2.75 1.51–4.81
T4 21 31 38 <0.001 3.91 1.96–7.83
Grade <0.001
Grade I 36 62 74 1
Grade II 369 47 62 0.007 2.46 1.39–4.02
Grade III 95 30 54 <0.001 4.82 2.42–9.75
LN stage <0.001
N1 185 58 79 1
N2 163 53 64 <0.001 1.959 1.362–2.819
N3 152 38 49 <0.001 3.479 2.457–4.926
LN ratio <0.001
60.2 150 68 85 1
0.2 & 60.65 190 50 63 <0.001 2.807 1.856–4.245
>0.65 160 28 43 <0.001 4.480 2.984–6.725
ER <0.001
ve 170 26 52 2.56 1.93–3.33
+ve 326 55 87 1
PR <0.001
ve 163 30 58 2.04 1.55–2.69
+ve 333 53 79 1
Figure 1 DFS of studied cases classiﬁed according to the LN
ratio.
Table 3 Multivariate analysis of the effects of prognostic
variables on disease free survival.
Variable p Hazard ratio 95.0% CI
Grade 0.004
Grade I 1
Grade II 0.11 2.2 0.8–3.8
Grade III 0.004 3.4 2.1–7.1
LN ratio 0.01
60.2 1
0.2 and 60.65 .01 2.2 1.5–4.9
>0.65 0.003 3.2 1.9–5.5
ER 0.01
+ve 1
ve 2.1 1.4–3.3
34 T.R. Elkhodary et al.group patients with increasing absolute number of positive
nodes into increasingly higher nodal stages: pathologic pN1,
one to three positive nodes; pN2, four to nine positive nodes;
pN3, 10 or more positive nodes [8]. Thus, the likelihood of
ﬁnding all of the positive nodes in the axilla is dependent on
the extent of axillary dissection and the extent of pathologic
examination. There is evidence that the likelihood of ﬁnding
positive nodes in the axilla increases with the number of nodes
removed. Therefore, in the current staging system, the prog-
nostic value of the absolute number of nodes removed for pre-
dicting disease burden in the axilla is confounded by the
number of nodes removed.In a developing country like Egypt, a proportion of breast
surgeries was performed at low-volume community hospitals
with less than optimal axillary lymph nodes retrieval [20]. In
our series where some patients are operated prior to referral
to our center, 93 cases (18.4%) had inadequate axillary dissec-
tion, i.e. <10 lymph nodes. LNR may be considered as an
alternative prognostic factor that may overcome that limita-
tion. The utility of this variable has been tested and proven
in several published reports and summarized in the meta-anal-
ysis of Woodward et al. [10].
In exploring the prognostic value of LNR in our series, we
elected to use the same cutoff points identiﬁed by Vinh-Hung
et al. [9], despite as the authors indicated, that different
authors have used different cutoff points to classify patients
into several risk groups [21–23].
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tumor grade were the only factors that were found to inﬂuence
DFS in the multivariate analysis. Patients with intermediate
and high LNRs were associated with a hazard ratio of recur-
rence of 2.2 and 3.2, respectively as compared with those in
the low risk category.
Analysis of the OS only identiﬁed ER- tumor as the only
prognostic factor associated with an increased risk of dying
from breast cancer. It is conceivable that the infrequent
number of deaths, so far, may account of the failure of identi-
fying the prognostic value of other variables. Perhaps, reanal-
ysis of this series after a longer follow-up may reveal the
inﬂuence of additional variables. This was clear in a similar ret-
rospective Lebanese study that included patients diagnosed
with breast cancer over a longer period (21 years). On univar-
iate analysis, both the absolute number of positive lymph
nodes and the LNR were signiﬁcant predictors of OS. On mul-
tivariate analysis, only the LNR remained an independent pre-
dictor of OS, with a 2.5-fold increased risk of dying at an LNR
of P0.25 [24].
Conclusion
The analysis of survival outcome of Egyptian patients with
early breast cancer identiﬁed the adverse prognostic effects
of high tumor grade, ER negativity, and intermediate and high
LNR on DFS. Our ﬁndings reinforce the importance of LNR
rather than the pN staging as an important prognostic variable
in breast cancer and it may replace the use of absolute number
of axillary lymph nodes.
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